Literature DB >> 33835970

A National Assessment of Optimal Oncologic Surgery for Distal Pancreatic Adenocarcinomas.

Katherine Hrebinko1, Samer Tohme, Richard S Hoehn, Samer AlMasri, Sidrah Khan, Christof Kaltenmeier, Kenneth K Lee, Alessandro Paniccia, Amer Zureikat, Ibrahim Nassour.   

Abstract

OBJECTIVES: The objective of this study was to create a composite measure, optimal oncologic surgery (OOS), for patients undergoing distal pancreatectomy for pancreatic adenocarcinoma and identify factors associated with OOS.
METHODS: Adult patients undergoing distal pancreatectomy were identified from the National Cancer Database between 2010 and 2016. Patients were stratified based on receipt of OOS. Criteria for OOS included 90-day survival, no 30-day readmission, length of stay ≤7 days, negative resection margins, ≥12 lymph nodes harvested, and receipt of chemotherapy. Multivariate logistic regression was performed to identify predictors of OOS. Survival curves and a Cox proportional hazards model were created to compare survival and identify risk factors for mortality.
RESULTS: Three thousand five hundred forty-six patients were identified. The rate of OOS was 22.3%. Diagnosis after 2012, treatment at an academic medical center, and a minimally invasive surgical approach (MIS) were associated with OOS. Survival was superior for patients undergoing OOS. Decreasing age at diagnosis, fewer comorbidities, surgery at an academic medical center, MIS, and lower pathologic stage were also associated with improved survival on multivariate analysis.
CONCLUSIONS: Rates of OOS for distal pancreatectomy are low. Time trends show increasing rates of OOS that may be related to increasing MIS, adjuvant chemotherapy, and referrals to academic medical centers.
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.

Entities:  

Mesh:

Year:  2021        PMID: 33835970      PMCID: PMC8670387          DOI: 10.1097/MPA.0000000000001786

Source DB:  PubMed          Journal:  Pancreas        ISSN: 0885-3177            Impact factor:   3.327


  38 in total

1.  Reducing Readmissions after Pancreatectomy: Limiting Complications and Coordinating the Care Continuum.

Authors:  Eugene P Ceppa; Henry A Pitt; Attila Nakeeb; C Max Schmidt; Nicholas J Zyromski; Michael G House; E Molly Kilbane; Alisha N George-Minkner; Beth Brand; Keith D Lillemoe
Journal:  J Am Coll Surg       Date:  2015-05-27       Impact factor: 6.113

2.  Improved perioperative outcomes with minimally invasive distal pancreatectomy: results from a population-based analysis.

Authors:  Hop S Tran Cao; Nicole Lopez; David C Chang; Andrew M Lowy; Michael Bouvet; Joel M Baumgartner; Mark A Talamini; Jason K Sicklick
Journal:  JAMA Surg       Date:  2014-03       Impact factor: 14.766

3.  A new method of classifying prognostic comorbidity in longitudinal studies: development and validation.

Authors:  M E Charlson; P Pompei; K L Ales; C R MacKenzie
Journal:  J Chronic Dis       Date:  1987

4.  Using a modification of the Clavien-Dindo system accounting for readmissions and multiple interventions: defining quality for pancreaticoduodenectomy.

Authors:  Marshall S Baker; Karen L Sherman; Susan J Stocker; Amanda V Hayman; David J Bentrem; Richard A Prinz; Mark S Talamonti
Journal:  J Surg Oncol       Date:  2014-05-26       Impact factor: 3.454

5.  Pancreatic Adenocarcinoma, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology.

Authors:  Margaret A Tempero; Mokenge P Malafa; Mahmoud Al-Hawary; Horacio Asbun; Andrew Bain; Stephen W Behrman; Al B Benson; Ellen Binder; Dana B Cardin; Charles Cha; E Gabriela Chiorean; Vincent Chung; Brian Czito; Mary Dillhoff; Efrat Dotan; Cristina R Ferrone; Jeffrey Hardacre; William G Hawkins; Joseph Herman; Andrew H Ko; Srinadh Komanduri; Albert Koong; Noelle LoConte; Andrew M Lowy; Cassadie Moravek; Eric K Nakakura; Eileen M O'Reilly; Jorge Obando; Sushanth Reddy; Courtney Scaife; Sarah Thayer; Colin D Weekes; Robert A Wolff; Brian M Wolpin; Jennifer Burns; Susan Darlow
Journal:  J Natl Compr Canc Netw       Date:  2017-08       Impact factor: 11.908

6.  Influence of resection margins on survival for patients with pancreatic cancer treated by adjuvant chemoradiation and/or chemotherapy in the ESPAC-1 randomized controlled trial.

Authors:  J P Neoptolemos; D D Stocken; J A Dunn; J Almond; H G Beger; P Pederzoli; C Bassi; C Dervenis; L Fernandez-Cruz; F Lacaine; J Buckels; M Deakin; F A Adab; R Sutton; C Imrie; I Ihse; T Tihanyi; A Olah; S Pedrazzoli; D Spooner; D J Kerr; H Friess; M W Büchler
Journal:  Ann Surg       Date:  2001-12       Impact factor: 12.969

7.  Cancer statistics, 2020.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2020-01-08       Impact factor: 508.702

8.  Curative resection is the single most important factor determining outcome in patients with pancreatic adenocarcinoma.

Authors:  M Wagner; C Redaelli; M Lietz; C A Seiler; H Friess; M W Büchler
Journal:  Br J Surg       Date:  2004-05       Impact factor: 6.939

9.  Optimal Pancreatic Surgery: Are We Making Progress in North America?

Authors:  Joal D Beane; Jeffrey D Borrebach; Amer H Zureikat; E Molly Kilbane; Vanessa M Thompson; Henry A Pitt
Journal:  Ann Surg       Date:  2019-10-28       Impact factor: 12.969

10.  Trends in pancreatic adenocarcinoma incidence and mortality in the United States in the last four decades; a SEER-based study.

Authors:  Anas M Saad; Tarek Turk; Muneer J Al-Husseini; Omar Abdel-Rahman
Journal:  BMC Cancer       Date:  2018-06-25       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.